Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study

Conclusion: Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing.

Source: Pharmacogenetics and Genomics - December 8, 2016 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research